Kailera Therapeutics, Inc.

KLRA

Figures shown here come from public SEC filings. Dates beside each section show the available history.

Annual Financial Review

Annual financial history is not available for this company.

SEC filings supply these figures; updates after the dates shown are not included. No annual financial history is available for this company. The latest insider filing shown is dated Jun 11, 2026.

Ownership

Who holds the shares, as reported in SEC ownership filings.

Independent insiders buying near the same time

2026-04-20–2026-04-20: 5 event(s) across 5 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing )

Purchases & sales (open market or private)

		Security	Code		Price	Filing
2026-04-20	Bain Capital Life Sciences Investors, LLC · 10% owner	Common Stock	P — Open market or private purchase	+1,562,500	16.00	SEC filing
2026-04-20	BAIN CAPITAL INVESTORS LLC · 10% owner	Common Stock	P — Open market or private purchase	+8,398,438	16.00	SEC filing
2026-04-20	Koppel Adam · Director, 10% owner	Common Stock	P — Open market or private purchase	+1,562,500	16.00	SEC filing
2026-04-20	RTW INVESTMENTS, LP · 10% owner	Common Stock	P — Open market or private purchase	+500,000	16.00	SEC filing
2026-04-20	Kaplan Andrew T. · Director, 10% owner	Common Stock	P — Open market or private purchase	+8,398,438	16.00	SEC filing

Showing 5 of 5 rows

Grants, exercises, tax & gifts

		Security	Code		Filing
2026-06-09	Renaud Ronald C JR · CEO & President	Common Stock	M — Exercise or conversion of derivative security	+38,094	SEC filing
2026-06-09	Renaud Ronald C JR · CEO & President	Stock Option (right to buy)	M — Exercise or conversion of derivative security	−38,094	SEC filing
2026-04-20	RTW INVESTMENTS, LP · 10% owner	Series A Preferred Stock	C — Conversion of derivative security	−8,250,000	SEC filing
2026-04-20	BAIN CAPITAL INVESTORS LLC · 10% owner	Series B Preferred Stock	C — Conversion of derivative security	−17,857,143	SEC filing
2026-04-20	Kaplan Andrew T. · Director, 10% owner	Common Stock	C — Conversion of derivative security	+17,857,143	SEC filing
2026-04-20	Koppel Adam · Director, 10% owner	Series B Preferred Stock	C — Conversion of derivative security	−4,145,768	SEC filing
2026-04-20	Bain Capital Life Sciences Investors, LLC · 10% owner	Common Stock	C — Conversion of derivative security	+16,875,000	SEC filing
2026-04-20	Bain Capital Life Sciences Investors, LLC · 10% owner	Series A-1 Preferred Stock	C — Conversion of derivative security	−16,875,000	SEC filing

Showing 8 of 20 rows

These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.